Literature DB >> 15533363

Characterizing ectopic pregnancies that rupture despite treatment with methotrexate.

Paul S Dudley1, Michael J Heard, Haleh Sangi-Haghpeykar, Sandra A Carson, John E Buster.   

Abstract

OBJECTIVE: To identify risk factors for tubal rupture among ectopic pregnancies treated with methotrexate (MTX).
DESIGN: Retrospective case-control analysis.
SETTING: An urban medical center. PATIENT(S): Eighty-one women diagnosed with an ectopic gestation treated with MTX: 19 patients experienced subsequent tubal rupture, and 62 patients experienced ectopic resolution. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Predictive variables including serial human chorionic gonadotropin (hCG) values. RESULT(S): The hCG incremental rate before as well as after MTX administration was positively associated with tubal rupture. HCG values prior to ectopic diagnosis that increased at least 66% over 48 hours and rising hCG values after treatment with methotrexate were independent predictors of tubal rupture. A disproportionate number (47%) of ectopic pregnancies that ruptured were located in the tubal isthmus. CONCLUSION(S): The hCG incremental rate both before and after MTX represents an independent risk factor for subsequent tubal rupture. Concentrations of hCG before ectopic diagnosis that increased at least 66% over 48 hours, or persistently rising hCG concentrations after treatment with MTX, may lower the threshold for surgical intervention. Implantation site may represent an unidentifiable risk factor for tubal rupture.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15533363     DOI: 10.1016/j.fertnstert.2004.03.066

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  7 in total

Review 1.  Medical management of ectopic pregnancy: a comparison of regimens.

Authors:  Emelia Argyropoulos Bachman; Kurt Barnhart
Journal:  Clin Obstet Gynecol       Date:  2012-06       Impact factor: 2.190

2.  [Factors associated with the failure of medical treatment for ectopic pregnancy: case study conducted at the Yaoundé Gynaecology, Obstetrics and Pediatrics Hospital].

Authors:  Pascal Foumane; Esther Juliette Ngo Um Meka; Félix Essiben; Émeric Lionel Botsomogo; Julius Dohbit Sama; Isidore Tompeen; Etienne Belinga; Emile Mboudou
Journal:  Pan Afr Med J       Date:  2022-03-11

3.  Assessment of early decline in the percentage of β-hCG values between days 0 and 4 after methotrexate therapy in ectopic pregnancy for the prediction of treatment success.

Authors:  Ebru Celik; Ilgın Türkçüoğlu; Abdullah Karaer; Pinar Kırıcı; Sevil Eraslan
Journal:  J Turk Ger Gynecol Assoc       Date:  2013-09-01

Review 4.  Incidence, diagnosis and management of tubal and nontubal ectopic pregnancies: a review.

Authors:  Danielle M Panelli; Catherine H Phillips; Paula C Brady
Journal:  Fertil Res Pract       Date:  2015-10-15

5.  The Use of Single Dose Methotrexate in the Management of Ectopic Pregnancy and Pregnancy of Unknown Location: 10 Years' Experience in a Tertiary Center.

Authors:  Amer Mahmoud Sindiani; Eman Alshdaifat; Basil Obeidat; Rawan Obeidat; Hasan Rawashdeh; Hashem Yaseen
Journal:  Int J Womens Health       Date:  2020-12-22

6.  Efficacy of methotrexate therapy in patients with tubal pregnancy and a serum human chorionic gonadotropin level above 10,000 IU/L.

Authors:  Kidong Kim; Dong Hoon Suh; Hyun Hoon Cheong; Sang Ho Yoon; Taek-Sang Lee; Jae Hong No; Yong-Beom Kim
Journal:  Clin Exp Reprod Med       Date:  2014-03-14

7.  Trophoblastic infiltration in tubal pregnancy evaluated by immunohistochemistry and correlation with variation of Beta-human chorionic gonadotropin.

Authors:  Danyelle Farias Ferreira; Julio Elito Júnior; Edward Araujo Júnior; João Norberto Stavale; Luiz Camano; Antonio Fernandes Moron
Journal:  Patholog Res Int       Date:  2014-01-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.